- The European Commission has approved Horizon Therapeutics plc's (NASDAQ:HZNP) Uplizna (inebilizumab) as monotherapy for neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+).
- NMOSD is an autoimmune disease that attacks the optic nerve, spinal cord, brain, and brain stem.
- In the N-MOmentum pivotal clinical trial, Uplizna demonstrated a significant reduction in the risk of an NMOSD attack with only two infusions per year following the initial loading doses.
- Related: Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation.
- Additionally, 89% of patients in the AQP4-IgG+ group remained relapse-free during the six months post-treatment, and more than 83% of patients on treatment remained attack free for at least four years.
- The FDA approved Uplizna in June 2020.
- Price Action: HZNP shares are down 3.31% at $95.30 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks